Your browser doesn't support javascript.
loading
Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
Färkkilä, Anniina; Rodríguez, Alfredo; Oikkonen, Jaana; Gulhan, Doga C; Nguyen, Huy; Domínguez, Julieta; Ramos, Sandra; Mills, Caitlin E; Pérez-Villatoro, Fernando; Lazaro, Jean-Bernard; Zhou, Jia; Clairmont, Connor S; Moreau, Lisa A; Park, Peter J; Sorger, Peter K; Hautaniemi, Sampsa; Frias, Sara; D'Andrea, Alan D.
Afiliación
  • Färkkilä A; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Rodríguez A; Harvard Medical School, Boston, Massachusetts.
  • Oikkonen J; Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Gulhan DC; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Nguyen H; Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, México.
  • Domínguez J; Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Ramos S; Harvard Medical School, Boston, Massachusetts.
  • Mills CE; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Pérez-Villatoro F; Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, México.
  • Lazaro JB; Laboratorio de Citogenética, Instituto Nacional de Pediatría, Ciudad de México, México.
  • Zhou J; Laboratory of Systems Pharmacology, Harvard Medical School, Massachusetts.
  • Clairmont CS; Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Moreau LA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Park PJ; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Sorger PK; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Hautaniemi S; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Frias S; Harvard Medical School, Boston, Massachusetts.
  • D'Andrea AD; Laboratory of Systems Pharmacology, Harvard Medical School, Massachusetts.
Cancer Res ; 81(10): 2774-2787, 2021 05 15.
Article en En | MEDLINE | ID: mdl-33514515
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Regulación Neoplásica de la Expresión Génica / Proteína p53 Supresora de Tumor / Resistencia a Antineoplásicos / Proteína BRCA1 / Evolución Clonal / Inhibidores de Poli(ADP-Ribosa) Polimerasas Límite: Animals / Female / Humans Idioma: En Revista: Cancer Res Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Regulación Neoplásica de la Expresión Génica / Proteína p53 Supresora de Tumor / Resistencia a Antineoplásicos / Proteína BRCA1 / Evolución Clonal / Inhibidores de Poli(ADP-Ribosa) Polimerasas Límite: Animals / Female / Humans Idioma: En Revista: Cancer Res Año: 2021 Tipo del documento: Article